What is the market's earnings forecast for Option Care next quarter?

What guidance did Option Care's management provide for the next earnings period?

What does Option Care do and what are its main business segments?

What is the revenue and EPS growth rate for Option Care year over year?

What factors drove the changes in Option Care's revenue and profit?

What is Option Care's gross profit margin?

What is Option Care's latest dividend and current dividend yield?

What were the key takeaways from Option Care's earnings call?

- **Revenue Momentum**: 12% YoY growth driven by acute therapy gains and chronic portfolio expansion, despite Stelara biosimilar headwinds.
- **Strategic Investments**: Advanced practitioner model expanded to 24 locations; 3 new tech apps launched to enhance efficiency.
- **Financial Strength**: Raised full year guidance to $5.6B-$5.65B revenue, $1.68-$1.72 EPS, supported by $223M cash flow generation.
- **Risk Management**: 2025 Stelara impact capped at $70M, but 2026 biosimilar uptake and new therapy launches pose uncertainty.
- **Capital Allocation**: Prioritizing growth investments (infusion suites, tech) over buybacks, with disciplined M&A approach.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue grew 12% YoY, driven by mid-teens growth in acute therapies and low double-digit growth in chronic therapies. Acute growth benefited from a competitive landscape shift, while chronic growth included new therapies and services.
- **Stelara Biosimilar Impact**: Uptake of Stelara biosimilars reduced gross profit by 380 basis points, with expectations for continued headwinds in 2026. The company is focused on minimizing the impact through portfolio diversification.
- **Strategic Initiatives**: Expanded advanced practitioner model to 24 locations, launched 3 new technology applications for efficiency, and integrated the Intramed Plus acquisition. Infusion suite utilization grew to 34% of nursing visits.
- **Market Positioning**: Emphasized home and alternate site care as cost-effective solutions, with partnerships in bed day management and site of care programs to reduce payer MLR.

**【CFO Financial Commentary】**
- **Financial Performance**: Q3 2025 revenue $1.4B, adjusted EBITDA $119.5M (3.4% YoY growth), adjusted EPS $0.45 (9.8% YoY). Full year guidance raised to $5.6B-$5.65B revenue, $468M-$473M EBITDA, $1.68-$1.72 EPS.
- **Cash Flow & Capital Allocation**: Generated $223M year-to-date cash flow, refinanced debt to reduce costs, and repurchased $62M in shares. Priorities: internal growth investments, M&A tuck-ins, and shareholder returns.
- **Cost Management**: G&A up 10% YoY due to acquisition costs, variable comp normalization, and technology investments. Gross margin pressured by Stelara biosimilar and rare therapy margins.

**【Q&A Highlights】**
- **Stelara Outlook**: 2025 impact $65M-$70M, with Q4 drag similar to Q3. 2026 uncertainty due to biosimilar uptake and new therapy launches (TREMFYA, Skyrizi). No exit plans despite margin compression.
- **M&A Strategy**: Focused on tuck-ins and near adjacencies (e.g., nursing agencies, tech platforms). Private multiples (2x+ EV/EBITDA) justify disciplined approach.
- **Regulatory Environment**: Navigating IRA and MFN pricing risks, with minimal 2025 impact. Long-term focus on value-based care partnerships.
- **Advanced Practitioner Model**: 175 facilities with 24 advanced practitioners, targeting higher acuity patients. Regulatory challenges (e.g., corporate practice of medicine) may slow expansion.
- **Gross Margin Risks**: Biosimilar pricing and rare therapy margins expected to weigh on gross profit, but diversified portfolio mitigates risk.

Option Care Health, Inc. (OPCH) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

OPCH

OPCH fundamentals

You can ask Aime